|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y,
Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal
cancer in Japan and China. J Epidemiol. 23:233–242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kato K, Cho BC, Takahashi M, Okada M, Lin
CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, et al:
Nivolumab versus chemotherapy in patients with advanced oesophageal
squamous cell carcinoma refractory or intolerant to previous
chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label,
phase 3 trial. Lancet Oncol. 20:1506–1517. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim JH, Ahn B, Hong SM, Jung HY, Kim DH,
Choi KD, Ahn JY, Lee JH, Na HK, Kim JH, et al: Real-world efficacy
data and predictive clinical parameters for treatment outcomes in
advanced esophageal squamous cell carcinoma treated with immune
checkpoint inhibitors. Cancer Res Treat. 54:505–516. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Farhood B, Najafi M and Mortezaee K: CD8+
cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell
Physiol. 234:8509–8521. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ikoma T, Shimokawa M, Matsumoto T, Boku S,
Yasuda T, Shibata N, Kurioka Y, Takatani M, Nobuhisa T, Namikawa T,
et al: Inflammatory prognostic factors in advanced or recurrent
esophageal squamous cell carcinoma treated with nivolumab. Cancer
Immunol Immunother. 72:427–435. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu J, Green MD, Li S, Sun Y, Journey SN,
Choi JE, Rizvi SM, Qin A, Waninger JJ and Lang X: Liver metastasis
restrains immunotherapy efficacy via macrophage-mediated T cell
elimination. Nat Med. 27:152–164. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sasaki A, Nakamura Y, Mishima S, Kawazoe
A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, et al:
Predictive factors for hyperprogressive disease during nivolumab as
anti-PD1 treatment in patients with advanced gastric cancer.
Gastric Cancer. 22:793–802. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA,
Atkins MB and Leming PD: Five-year survival and correlates among
patients with advanced melanoma, renal cell carcinoma, or non-small
cell lung cancer treated with nivolumab. JAMA Oncol. 5:1411–1420.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee JC, Mehdizadeh S, Smith J, Young A,
Mufazalov IA, Mowery CT, Daud A and Bluestone JA: Regulatory T cell
control of systemic immunity and immunotherapy response in liver
metastasis. Sci Immunol. 5:eaba07592020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumagai S, Koyama S, Itahashi K,
Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono
H, et al: Lactic acid promotes PD-1 expression in regulatory T
cells in highly glycolytic tumor microenvironments. Cancer Cell.
40:201–218.e9. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Templeton AJ, McNamara MG, Šeruga B,
Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106:dju1242014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Ma W, Qiu Z, Kuang T, Wang K, Hu
B and Wang W: Prognostic nutritional index as a prognostic
biomarker for gastrointestinal cancer patients treated with immune
checkpoint inhibitors. Front Immunol. 14:12199292023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakahama K, Izumi M, Yoshimoto N, Fukui M,
Sugimoto A, Nagamine H, Ogawa K, Sawa K, Tani Y, Kaneda H, et al:
Influence of smoking history on the effectiveness of
immune-checkpoint inhibitor therapy for non-small cell lung cancer:
Analysis of real-world data. Anticancer Res. 43:2185–2197. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun Y, Yang Q, Shen J, Wei T, Shen W,
Zhang N, Luo P and Zhang J: The effect of smoking on the immune
microenvironment and immunogenicity and its relationship with the
prognosis of immune checkpoint inhibitors in non-small cell lung
cancer. Front Cell Dev Biol. 9:7458592021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang X, Ricciuti B, Alessi JV, Nguyen T,
Awad MM, Lin X, Johnson BE and Christiani DC: Smoking history as a
potential predictor of immune checkpoint inhibitor efficacy in
metastatic non-small cell lung cancer. J Natl Cancer Inst.
113:1761–1769. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giustini N and Bazhenova L: Recognizing
prognostic and predictive biomarkers in the treatment of non-small
cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs).
Lung Cancer (Auckl). 12:21–34. 2021.PubMed/NCBI
|
|
18
|
Sacdalan DB, Lucero JA and Sacdalan DL:
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in
patients receiving immune checkpoint inhibitors: A review and
meta-analysis. Onco Targets Ther. 11:955–965. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie X, Liu J, Yang H, Chen H, Zhou S, Lin
H, Liao Z, Ding Y, Ling L and Wang X: Prognostic value of baseline
neutrophil-to-lymphocyte ratio in outcome of immune checkpoint
inhibitors. Cancer Invest. 37:265–274. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muhammed A, Fulgenzi CAM, Dharmapuri S,
Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Saeed A,
Hildebrand H, et al: The systemic inflammatory response identifies
patients with adverse clinical outcome from immunotherapy in
hepatocellular carcinoma. Cancers (Basel). 14:1862021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chau I, Ajani JA, Doki Y, Xu J, Wyrwicz L,
Motoyama S, Ogata T, Kawakami H, Hsu C, Adenis A, et al: Nivolumab
(NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo
as first-line (1L) treatment for advanced esophageal squamous cell
carcinoma (ESCC): Expanded efficacy and safety analyses from
CheckMate 648. J Clin Oncol. 40 (Suppl 16):S4035. 2022. View Article : Google Scholar
|
